Psychiatric uses of antiepileptic treatments

Epilepsy and Behavior

Volumn 3, Issue 5 SUPPL. 1, 2002, Pages 54-59

  Boylan, Laura S ^a   Devinsky, Orrin ^a   Barry, John J ^b   Ketter, Terence A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggression; Agitation; Antiepileptic drug; Anxiety; Behavioral neurology; Bipolar disorder; Depression; Epilepsy; Psychiatry; Side effects

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; METHYLPHENOBARBITAL; NOOTROPIC AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PLACEBO; PRIMIDONE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGITATION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BRAIN DISEASE; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG USE; FATIGUE; HUMAN; HYPERACTIVITY; IMPOTENCE; IMPULSE CONTROL DISORDER; INSOMNIA; LIVER TOXICITY; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; NAUSEA AND VOMITING; NEUROTOXICITY; PATIENT SELECTION; PERSONALITY DISORDER; PSYCHOSIS; RASH; REVIEW; RISK BENEFIT ANALYSIS; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; TERATOGENICITY; VAGUS NERVE STIMULATION;

EID: 0036816446     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1525-5069(02)00501-7     Document Type: Review

References (63)

1. De Leon OA. Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder. Harv Rev Psychiatry 2001;9:209-22.
2. Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 1997;154:291-2.
3. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1997;59:426-9.
4. Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851-3.
5. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2:249-55.
6. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-14.
7. Ketter TA, Post RM, Theodore WH. Positive and negative psychotropic effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53:S52-66.
8. Gates JR. Side effect profiles and behavioral consequences of antiepileptic medications. Epilepsy Behav 2000;1:153-9.
9. Devinsky O, D'Esposito M. Principles of cognitive and behavioral neurology. New York: Oxford University Press; 2003.
10. Stein G. Drug treatment of the personality disorders. Br J Psychiatry 1992;16:167-84.
11. Keck PE, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992;12:S36-41.
12. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988;145: 1104-9.
13. Lima AR, Lima MS, Soares BG, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev 2001;4: CD002023.
14. Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence? J Clin Psychiatry 2002;63:218-24.
15. Friedman DL, Kastner T, Plummer AT. Adverse behavioral effects in individuals with mental retardation and mood disorders treated with carbamazepine. Am J Ment Retard 1992;96:541-6.
16. Ketter TA, Malow BA, Flamini R, et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996;23:129-37.
17. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Psychopharmacol 1999;19:341-8.
18. Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999;40:1129-34.
19. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
20. Dodrill CB, Arnett JL, Hayes AG, et al. Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res 1999;35:109-21.
21. Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA. Behavioral side effects of gabapentin in children. Epilepsia 1996;37:87-90.
22. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
23. Calabrese JR, Suppes P, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-50.
24. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51: 333-43.
25. Erfurth A, Walden J, Grunze H. Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 1998;38:204-5.
26. Meador KJ, Baker GA. Behavioral and cognitive effects of lamotrigine. J Child Neurol 1997;12:S44-7.
27. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in epilepsy patients with mental retardation. Epilepsia 1998;39:874-7.
28. Rickles NM, Gidal BE, Collins M, et al. Possible association of behavioral disturbances with levetiracetam: report of a case series [abstract]. Epilepsia 2001;42:259.
29. Emrich HM. Studies with (Trileptal) oxcarbazepine in acute mania. Int Clin Psychopharmacol 1990;5:S83-8.
30. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry 2001;34:242-50.
31. Besag FM. Behavioural effects of the new anticonvulsants. Drug Saf 2001;24:513-36.
32. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000;157:463-5.
33. Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995;36:S46-65.
34. Murphy J, Motiwala R, Devinsky O. Phenytoin intoxication. South Med J 1991;84:1199-204.
35. Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39:33-42.
36. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36: S10-3.
37. Carta MG, Hardoy MC, Grunze H, Carpiniello B. The use of tiagabine in affective disorders. Pharmacopsychiatry 2002;35:33-4.
38. Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999;60:759-62.
39. Grunze HC, Normann C, Langosch J, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001;62:464-8.
40. Calabrese JR, Keck Jr PE, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001;21:340-2.
41. Calabrese JR. Personal communication, May 2002.
42. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-72.
43. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52:1882-7.
44. Fakhoury T, Murray L, Seger D, McLean M, Bassel A. Topiramate overdose: clinical and laboratory features. Epilepsy Behav 2001;3:185-9.
45. Pope Jr HG, McElroy SL, Keck Jr PE, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991;48:62-8.
46. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108-11.
47. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-24.
48. Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997;154:1456-8.
49. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
50. Davis LL, Ryan W, Adinoff B, et al. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000;20:S1-S17.
51. Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994;14:311-3.
52. Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13:448-51.
53. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998;43:73-7.
54. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995;56:506-10.
55. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000;61:123-8.
56. Winterer G, Hermann WM. Valproate and the symptomatic treatment of schizophrenia spectrum patients. Pharmacopsychiatry 2000;33:182-8.
57. Casey D, Daniel D, Tracy K, Wozniak P, Sommerville K. Improved antipsychotic effect of divalproex combined with risperidone or olanzapine for schizophrenia. Neuropsychopharmacology 2002; in press.
58. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999;53:1503-11.
59. Kanba S, Yagi G, Kamijima K, Suzuki T, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994;18: 707-15.
60. Rush AJ, George MS, Sackiem HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000;47:276-86.
61. Bruins JB. Cyberonics. Personal communication.
62. Devinsky O. What do you do when they grow up? Approaches to seizures in developmentally delayed adults. Epilepsia 2002; 43(Suppl 3):71-9.
63. Blumer D, Davies K, Alexander A, Morgan S. Major psychiatric disorders subsequent to treating epilepsy by vagus nerve stimulation. Epilepsy Behav 2001;2:466-72.